211 related articles for article (PubMed ID: 18607591)
1. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetically guided dosing of carboplatin in paediatric cancer patients with bilateral nephrectomy.
Veal GJ; English MW; Grundy RG; Shakespeare C; Glaser A; Waters F; Holden V; O'Meara A; Michalski A; Howe K; Cole S; Boddy AV
Cancer Chemother Pharmacol; 2004 Oct; 54(4):295-300. PubMed ID: 15133627
[TBL] [Abstract][Full Text] [Related]
4. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
Warren K; Gervais A; Aikin A; Egorin M; Balis FM
Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
[TBL] [Abstract][Full Text] [Related]
6. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
7. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
8. Topotecan combination chemotherapy in two new rodent models of retinoblastoma.
Laurie NA; Gray JK; Zhang J; Leggas M; Relling M; Egorin M; Stewart C; Dyer MA
Clin Cancer Res; 2005 Oct; 11(20):7569-78. PubMed ID: 16243833
[TBL] [Abstract][Full Text] [Related]
9. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
10. Iontophoretic delivery of carboplatin in a murine model of retinoblastoma.
Hayden B; Jockovich ME; Murray TG; Kralinger MT; Voigt M; Hernandez E; Feuer W; Parel JM
Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):3717-21. PubMed ID: 16936078
[TBL] [Abstract][Full Text] [Related]
11. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma.
Van Quill KR; Dioguardi PK; Tong CT; Gilbert JA; Aaberg TM; Grossniklaus HE; Edelhauser HF; O'Brien JM
Ophthalmology; 2005 Jun; 112(6):1151-8. PubMed ID: 15885791
[TBL] [Abstract][Full Text] [Related]
12. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.
Abramson DH; Frank CM; Dunkel IJ
Ophthalmology; 1999 Oct; 106(10):1947-50. PubMed ID: 10519590
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
15. A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy.
Lambert MP; Shields C; Meadows AT
Pediatr Blood Cancer; 2008 Feb; 50(2):223-6. PubMed ID: 17278120
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of systemic versus focal Carboplatin chemotherapy in the rabbit eye: possible implication in the treatment of retinoblastoma.
Hayden BC; Jockovich ME; Murray TG; Voigt M; Milne P; Kralinger M; Feuer WJ; Hernandez E; Parel JM
Invest Ophthalmol Vis Sci; 2004 Oct; 45(10):3644-9. PubMed ID: 15452072
[TBL] [Abstract][Full Text] [Related]
17. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.
Veal GJ; Errington J; Sastry J; Chisholm J; Brock P; Morgenstern D; Pritchard-Jones K; Chowdhury T
Cancer Chemother Pharmacol; 2016 Apr; 77(4):685-92. PubMed ID: 26875154
[TBL] [Abstract][Full Text] [Related]
18. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of periocular topotecan in children with intraocular retinoblastoma.
Chantada GL; Fandino AC; Carcaboso AM; Lagomarsino E; de Davila MT; Guitter MR; Rose AB; Manzitti J; Bramuglia GF; Abramson DH
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1492-6. PubMed ID: 18978345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
